Answers are grounded in this paper and cite their sources.
Identifying a therapeutic dose requires simultaneous consideration of efficacy and toxicity while controlling erroneous statistical conclusions across multiple dose levels. This study develops a joint confidence-based framework for identifying the minimum effective dose (MinED) and maximum safe dose (MaxSD) in trials with binary endpoints. The proposed approach integrates simultaneous confidence bounds, stepwise testing and the partitioning principle to characterise dose boundaries while addressing multiplicity. The theoretical framework establishes strong familywise error rate (FWER) control when the underlying joint confidence region achieves its required simultaneous coverage. A simultaneously adjusted Farrington–Manning score-based implementation was evaluated through a clinical illustration and simulation studies involving varying sample sizes, treatment effects and efficacy–toxicity dependence structures. The clinical illustration identified 100 mg as the only investigated dose satisfying both prespecified efficacy and safety criteria. Simulation results demonstrated favourable empirical FWER control, simultaneous coverage close to the nominal level and greater dose-identification power than a conservative exact-binomial benchmark, particularly with increasing sample sizes and treatment effects. These findings demonstrate the potential of simultaneous confidence-based inference for therapeutic-window identification, while highlighting the need for further finite-sample validation of the approximate score-based implementation.
No takes yet. Share an insight, caveat, or question.
Awaab et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: